Stockreport

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-l...

AstraZeneca PLC - American Depositary Shares  (AZN) 
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER [Read more]